Bionomics Limited
NASDAQ:BNOX
Overview | Financials
Company Name | Bionomics Limited |
Symbol | BNOX |
Currency | USD |
Price | 0.253 |
Market Cap | 891,889,020 |
Dividend Yield | 0% |
52-week-range | 0.242 - 18 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Spyridon Papapetropoulos M.D., Ph.D. |
Website | https://www.bionomics.com.au |
An error occurred while fetching data.
About Bionomics Limited
Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia and the United States. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which has completed phase 2
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD